Stem Cell Therapeutics Corp.

Stem Cell Therapeutics Corp.

March 30, 2009 08:40 ET

Stem Cell Therapeutics Corp. Announces Presentation by Dr. Joshua M. Hare on NTx-265® Animal Data After Post-Myocardial Infarction in the Heart

CALGARY, ALBERTA--(Marketwire - March 30, 2009) - Stem Cell Therapeutics Corp. (the "Company" or "SCT") (TSX VENTURE:SSS) announced today that Dr. Joshua M. Hare, MD, FACC, Louis Lemberg Professor of Medicine and Director, Interdisciplinary Stem Cell Institute (ISCI) at the University of Miami, presented the "Effects of Combination of Proliferative Agents and Erythropoeitin (EPO) on Left Ventricular Remodeling Post-Myocardial Infarction" at the 58th Annual American College of Cardiology Conference in Orlando, Florida.

The study, conducted by Dr. Hare's team at the University of Miami, described the effects of two drug regimens: human Chorionic Gonadotropin (hCG) plus EPO (NTx-265® regimen) and a regimen composed of prolactin (PRL) then EPO. Both of the regimens were dosed in a similar manner, following a severe left ventricular coronary occlusion - heart attack - in rats.

The study demonstrated that after a severe myocardial infarction (MI), the left ventricle chamber dimension increased by approximately 200% and decreased in ejection fraction by about 44%. Systemic treatment with hCG, EPO or hCG plus EPO (NTx-265® regimen) significantly limited the expansion of ventricular chamber dimension and reversed the effects on ejection fraction by approximately 50%. Prolactin, however, did not have this effect.

Dr. Hare concluded "that hCG alone or in combination with EPO may be an effective therapeutic strategy to ameliorate post-MI remodeling. The absence of this same effect with PRL suggests a direct effect of on NTx-265® on the myocardium." Moreover, Dr. Hare also believes that "given the established safety profile of hCG in humans, clinical trials may be warranted as a next step."

Dr. Alan Moore, President and CEO, commented as follows:

"This recently completed study by Dr. Hare builds upon earlier observations that NTx-265® modulates the activity of a population of cells within the adult heart. We are pleased to now have the confirmation of a long suspected positive effect on recovery following heart attack. The exciting, novel study results suggest that an entirely new therapeutic drug approach may be possible in the heart and emphasizes the enormous potential that is captured within SCT's patent portfolio."

About Stem Cell Therapeutics Corp.: Stem Cell Therapeutics Corp. is a Canadian public biotechnology company (TSX VENTURE:SSS) focused on the development and commercialization of drug-based therapies to treat central nervous system diseases. SCT is a leader in the development of therapies that utilize drugs to stimulate a patient's own resident stem cells. The Company's programs aim to repair neurological function lost due to disease or injury. SCT's extensive patent portfolio of owned and licensed intellectual property supports the potential expansion into future clinical programs in numerous neurological diseases such as traumatic brain injury, multiple sclerosis, Huntington's disease, Alzheimer's disease, and ALS.

For further information on Stem Cell Therapeutics Corp., visit

These securities have not been registered under the United States Securities Act of 1933, as amended, or the securities laws of any state, and may not be offered or sold within the United States or to, or for the account or benefit of U.S. persons unless an applicable exemption from U.S. registration requirements is available.

Except for historical information, this press release may contain forward-looking statements, which reflect the Company's current expectation regarding future events. These forward-looking statements involve risk and uncertainties, which may cause but are not limited to, changing market conditions, the successful and timely completion of clinical studies, the establishment of corporate alliances, the impact of competitive products and pricing, new product development, uncertainties related to the regulatory approval process and other risks detailed from time to time in the Company's ongoing quarterly and annual reporting.

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Contact Information